CONTACT: Brenda Nashawaty, bnashawaty@adverahealth.com, +1 617-688-3253

COLUMBIA UNIVERSITY AND ADVERA HEALTH ANALYTICS TO RELEASE
REPORT DIRECTLY LINKING ADVERSE DRUG EVENTS WITH DOWNSTREAM MEDICAL COSTS TO PROVIDE A DRUG'S ACTUAL TOTAL FINANCIAL IMPACT
AT AMCP NEXUS 2015

Impact Drug Safety Rating System Based On Post-Marketing Costs
Associated with Adverse Events and Patient Outcomes Study;
5+ Million AE Case Reports from 1997-2014 analyzed

ORLANDO, FL…October 26, 2015 – Advera Health Analytics, Inc. and Dr. Nicholas Tatonetti from Columbia University will present their joint study presented at the Academy of Managed Care Pharmacy (AMCP) 2015 Nexus educational conference in Orlando on October 26. The research poster is titled, "**Impact Drug Safety Rating System Based on Post-Marketing Costs Associated with Adverse Events And Patient Outcomes."**

There is an acute need for the development of analytics that reflect drug safety in heterogeneous, real world populations, due to multiple limitations associated with relatively homogeneous pre-approval clinical trials, inadequate data disclosures, slow reaction times from regulatory bodies, and deep rooted bias against disclosing and publishing negative results.

The effort undertaken by Advera Health Analytics and Dr. Nicholas Tatonetti, Assistant Professor of Biomedical Informatics at Columbia University, was to develop a drug safety statistic that estimates downstream medical costs associated with serious adverse events (AEs) and patient outcomes.

Over 5 million AE case reports from 1997-2014 were imported from FDA's post-marketing AE database known as the Adverse Event Reporting System (FAERS). All "primary suspect" case reports for each drug were collected from FAERS. Serious AEs and outcomes were MedDRA coded and tallied for each case report. Non-serious AEs and outcomes were not included. All costed cases were aggregated for each drug and divided by the number of patients exposed to obtain a downstream estimated direct medical cost burden per exposure. Each drug was assigned a corresponding 1-100 point total.

There is an enormous gap on quality data regarding drug safety in real world patient populations. The system demonstrates that post-marketing AE reports can be assigned direct medical costs in order to

estimate a drug's downstream financial impact, and thereby provide a needed window into drug safety in real world patient populations.

ABOUT NICHOLAS TATONETTI, PhD
Dr. Tatonetti is Assistant Professor of Biomedical Informatics, Columbia University.
The Tatonetti Lab is in the Department of Biomedical Informatics at Columbia as well as the Department of Systems Biology and the Department of Medicine, and is a member of the Data Science Institute at Columbia.

ABOUT ADVERA HEALTH ANALYTICS
Advera Health Analytics is a health informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of real world outcomes data. Advera Health Analytics makes these data accessible, actionable, and predictable. For more information visit adverahealth.com and connect with us on LinkedIn, Twitter and Facebook.